Diagnosis and Treatment of Renal Cell Carcinoma

Diagnostic Criteria

The European Association of Urology recommends that a solid renal mass with contrast enhancement is the most concerning ultrasound feature for Renal Cell Carcinoma (RCC), as this is the most important criterion for malignant lesions 1
The European Society for Medical Oncology suggests that solid appearance on ultrasound should prompt further evaluation with contrast-enhanced CT or MRI, as ultrasound is typically the initial imaging modality that suggests RCC diagnosis 2
The European Association of Urology states that contrast enhancement is the critical feature distinguishing malignant from benign lesions when contrast-enhanced ultrasound is performed 1
The European Urology guidelines indicate that complex cystic masses with thick or irregular walls, septations, and solid components are concerning and suggest a higher Bosniak classification (III-IV) 4, 1

The American Urological Association recommends that for localized RCC, surgical resection is the standard of care, with partial nephrectomy preferred for tumors ≤4 cm (T1a) to preserve renal function 5
The National Comprehensive Cancer Network suggests that partial nephrectomy should still be considered for T1b-T2 tumors (>4 cm but confined to kidney) when technically feasible; radical nephrectomy is appropriate for larger tumors or when partial nephrectomy is not feasible 5
The European Society for Medical Oncology recommends that radical nephrectomy with lymph node dissection is the standard approach for T3-T4 tumors (locally advanced) 3
The American Society of Clinical Oncology states that lymph node dissection should only be performed when clinically enlarged lymph nodes are present on imaging or discovered during surgical exploration, primarily for staging purposes 6

The European Society for Medical Oncology recommends that for metastatic RCC, first-line treatment consists of immune checkpoint inhibitor combinations or immune checkpoint inhibitors combined with tyrosine kinase inhibitors 3
The National Comprehensive Cancer Network suggests that for Clear Cell RCC, combination immune checkpoint inhibitor therapy or immune checkpoint inhibitor plus tyrosine kinase inhibitor is recommended for favorable and intermediate-risk patients 3
The American Society of Clinical Oncology states that temsirolimus is recommended as first-line therapy for poor-risk patients 5
The European Association of Urology guidelines indicate that everolimus is recommended as second-line therapy after tyrosine kinase inhibitor failure 5

The American Urological Association recommends that metastatic disease on systemic therapy should be monitored with imaging every 2-4 months with response assessment using RECIST criteria 3, 5
The National Comprehensive Cancer Network suggests that high-risk patients post-surgery should be followed up every 3-6 months for the first 2 years 5